Scoop: CellProthera eyes $30M round for PhIII trial of cell therapy for heart attacks: #Jefferies23

CellProthera plans to raise around $30 million in its first major fundraise to help advance its lead regenerative cell therapy program for patients who have recently experienced heart attacks into registrational development, Endpoints News has learned.

“We want to do the Phase III trial in both the US and EU, so we expect we need to raise as much as we’ve raised to date over several tranches, but this time in a single shot,” CEO Matthieu de Kalbermatten told Endpoints on Tuesday at the annual Jefferies healthcare conference in London.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。